⚠ Evidence warning: Clinical trials or other evidence do not support the claim that Pau d'Arco activates natural killer cells and helps recurrent colds, chronic sinusitis, post-viral fatigue, candida overgrowth and recurrent boils. This page keeps it as a report of what people, websites or other media say.

Pau d'Arco for Immune Modulation

Pau d'Arco's reputation in South American traditional medicine as a "blood purifier" (depurativo) for fevers, recurrent infection, slow-healing wounds, and chronic skin disease is the background to its use by integrative practitioners as an immune modulator. Practitioners describe the bark as activating innate immune cells — natural killer (NK) cells, macrophages, and dendritic cells — at low doses. The laboratory studies found run mostly the other way: in rat macrophages, beta-lapachone at concentrations without cytotoxic effects blocked the nitric oxide and tumor necrosis factor-α responses to bacterial lipopolysaccharide, and in mice a water extract of the inner bark shifted immune cells toward an anti-inflammatory pattern. This deep-dive walks through the immune mechanisms, the traditional Kallawaya and Guaraní indications, and the modern clinical applications — including the realistic limits of what a single herb can accomplish for chronic immune dysfunction.


Table of Contents

  1. "Blood Purifier" — The Traditional Depurative Concept and Its Modern Translation
  2. Hormetic Dose-Response — Why Sub-Cytotoxic Naphthoquinones Activate Immunity
  3. Natural Killer (NK) Cell Activation
  4. Macrophage Activation — Tumor Necrosis Factor-α, IL-12, Nitric Oxide
  5. Dendritic Cells and Antigen Presentation
  6. Th1 / Th2 Balance and Cytokine Shifting
  7. Kallawaya and Guaraní Indigenous Use — Fevers, Wound Healing, Chronic Infection
  8. Adult Applications — Recurrent Infection, Chronic Sinusitis, Post-Viral Recovery
  9. Combining With Other Immune Herbs — Echinacea, Astragalus, Reishi, Cat's Claw
  10. Cautions Specific to Immune-Modulating Use
  11. Key Research Papers
  12. Connections
  13. Featured Videos

"Blood Purifier" — The Traditional Depurative Concept and Its Modern Translation

The Spanish and Portuguese-Brazilian traditional medicine concept of depurativo ("blood purifier") is one of the oldest and most universal categories in folk pharmacy. A depurative herb is given for chronic skin eruptions, slow-healing wounds, recurrent boils, lymph node enlargement, low-grade fever of unknown origin, and "thick" or "bad" blood — conditions that, in the pre-microbiological era, were interpreted as an accumulation of impurities the body could not clear unaided. Pau d'Arco was one of the most reputable Brazilian and Argentinian depuratives, alongside sarsaparilla (Smilax), burdock root (Arctium), and dandelion root (Taraxacum) in the New World materia medica, paralleling the use of red clover, yellow dock, and cleavers in European tradition.

The modern translation of the depurative concept is reasonably coherent: most "bad blood" conditions in the pre-microbiological era were chronic low-grade infections (subclinical staphylococcal carriage, recurrent fungal disease, parasitic infestation, tuberculosis), chronic inflammatory disease (psoriasis, eczema, chronic dermatitis), or lymphatic congestion from any of these. A depurative that combines antimicrobial activity, immune stimulation, and anti-inflammatory effect — the profile practitioners attribute to Pau d'Arco — would empirically produce visible improvement in many of these conditions even without any understanding of the underlying biology.

This is not to say the traditional model was scientifically correct — "purifying the blood" is not a real biochemical operation — but the herbs selected as depuratives by careful folk observation across multiple continents tend, when subjected to modern bioactivity screening, to have genuine antimicrobial and immune-modulating profiles. Pau d'Arco fits this pattern.

Back to Table of Contents

Hormetic Dose-Response — Why Sub-Cytotoxic Naphthoquinones Activate Immunity

The unifying principle of Pau d'Arco's biphasic activity is hormesis: the phenomenon in which a low dose of a mildly toxic stressor produces an adaptive, beneficial response, while a high dose produces direct damage. Lapachol and beta-lapachone deposit reactive oxygen species (ROS) inside cells via redox cycling. At high concentrations, the reactive oxygen species load overwhelms cellular antioxidant defenses and triggers programmed cell death — this is the mechanism behind the antifungal and antitumor effects. At low concentrations, the same reactive oxygen species load is sub-lethal but sufficient to:

  1. Trigger Nrf2 (nuclear factor erythroid 2-related factor 2) translocation to the nucleus and upregulate the phase-2 antioxidant gene set (glutathione synthesis, NAD(P)H quinone oxidoreductase 1 (NQO1), heme oxygenase-1)
  2. Activate mitogen-activated protein kinase (MAPK) signaling cascades that prime immune cells for response
  3. Mildly increase intracellular calcium in macrophages and natural killer cells, lowering the threshold for activation by their conventional triggers
  4. Upregulate cytokine production (tumor necrosis factor-α, interleukin-12 (IL-12), interferon-gamma (IFN-γ)) in monocytes and dendritic cells, as the model predicts — although the macrophage studies below found beta-lapachone inhibiting the tumor necrosis factor-α response to lipopolysaccharide instead

This is the same hormetic principle that explains the immune-modulating effects of moderate exercise, hyperbaric oxygen therapy, sauna, cold exposure, intermittent fasting, and several other "stressor" interventions: a sub-lethal pulse of cellular stress trains the cell to handle larger insults. In this model, as integrative practitioners describe it, immune-stimulating doses of Pau d'Arco are lower than antifungal doses, not higher. No study of immune-stimulating doses of Pau d'Arco in people was found.

Back to Table of Contents

Natural Killer (NK) Cell Activation

Natural killer (NK) cells are large granular lymphocytes of the innate immune system that recognize and kill virus-infected and tumor cells through a non-antigen-specific mechanism. They are the body's first-line defense against intracellular viral infection and serve as a continuous tumor-surveillance system. Natural killer cytotoxic activity declines measurably with age, chronic stress, sleep deprivation, and several chronic disease states — and is one of the best-validated markers of overall immune competence.

Integrative practitioners describe Pau d'Arco as supporting natural killer cell activity. No laboratory or animal study measuring natural killer cell cytotoxicity, natural killer receptors, granzyme or perforin after Pau d'Arco extracts or beta-lapachone was found.

No human trial measuring natural killer cytotoxicity after Pau d'Arco was found. The integrative-medicine practice of including Pau d'Arco in chronic-fatigue, post-viral, and recurrent-infection protocols rests on the long traditional reputation and clinical experience reports rather than rigorous human randomized controlled trial (RCT) evidence.

The only human study of a lapacho product found was an uncontrolled phase II study in 40 adults having radiotherapy for head and neck cancer, who swallowed a lapacho-based mouth solution 3 times a day from the first day to the end of radiotherapy. Eleven (27.5%) developed grade 2 oral mucositis (mouth sores) and 4 (10%) grade 3, none developed grade 4, and no one stopped radiotherapy because of mucositis. The study had no comparison group, and its authors called for a phase III study to confirm the results (Giacomelli 2015).

For people with documented low natural killer function (measured by natural killer cell cytotoxicity assay, available from some specialty immunology labs), some integrative practitioners describe a 3-month course of low-dose Pau d'Arco (500-1,000 mg standardized extract twice daily) alongside other natural killer-supporting measures, with the cytotoxicity assay repeated at 3 months. This regimen comes from practice; it has not been tested in a published study.

Back to Table of Contents

Macrophage Activation — Tumor Necrosis Factor-α, IL-12, Nitric Oxide

Macrophages are the tissue-resident phagocytes that engulf and destroy bacteria, dead cells, and debris, and that produce the cytokines orchestrating the broader inflammatory response. They exist along a polarization spectrum from "M1" (classically activated, pro-inflammatory, antimicrobial) to "M2" (alternatively activated, tissue-repair, anti-inflammatory). The right macrophage state depends on context — acute infection needs M1 polarization, while chronic wound healing needs M2.

Practitioners describe Pau d'Arco as increasing macrophage phagocytic activity and interleukin-12 production and pushing macrophages toward the M1 state; no study showing these effects was found. The laboratory studies of lapachol-family compounds and the bark on macrophages found the opposite direction for the two markers they measured:

Taken by mouth at 100 mg/kg for 1 week, the same bark water extract completely diminished ear swelling caused by arachidonic acid in mice, though not swelling caused by croton oil (Byeon 2008). In laboratory work, then, the bark acts mainly as an anti-inflammatory rather than an immune stimulant.

Practitioners link the traditional use for indolent chronic infection to an M1-shifting effect, comparing it with the gamma-interferon or other macrophage-activating biologics modern medicine sometimes uses; the macrophage studies above found suppression of nitric oxide and tumor necrosis factor-α rather than such a shift.

In these studies the suppression was seen at concentrations without cytotoxic effects. Beta-lapachone also inhibited the protein tyrosine phosphorylation and nuclear factor kappa B (NF-κB) activation caused by lipopolysaccharide (Tzeng 2003) — the basis of the anti-inflammatory activity. The biphasic model practitioners describe — immune-stimulating at low dose, anti-inflammatory at intermediate dose, cytotoxic at high dose — was not borne out for the immune-stimulating step in these studies.

Back to Table of Contents

Dendritic Cells and Antigen Presentation

Dendritic cells (DCs) are the bridge between innate and adaptive immunity. They patrol the tissues, take up antigen, migrate to the regional lymph node, and present that antigen to naive T cells — initiating clonal expansion of antigen-specific effector cells. The quality of the DC response (which major histocompatibility complex (MHC) class, which co-stimulatory molecules, which cytokine context) largely determines whether the resulting adaptive response is Th1 (cellular immunity), Th2 (humoral, parasites), Th17 (mucosal defense), or Treg (regulatory tolerance).

No study was found showing Pau d'Arco extracts raising dendritic-cell maturation markers (the CD80, CD83 and CD86 co-stimulatory molecules or major histocompatibility complex class II) or interleukin-12. In the one study found on a Pau d'Arco extract and dendritic cells, a water extract of the inner bark (taheebo) given by mouth to mice made dendritic cells produce the immunosuppressive cytokine interleukin-10 (IL-10) and polarized macrophages toward an anti-inflammatory phenotype in the mesenteric lymph nodes. This resulted in "a significant increase in anti-inflammatory Th2 and Foxp3+ Treg cells and a dramatic decrease in pro-inflammatory Th1 and Th17 cells", and the extract reduced the weight loss and colon inflammation of chemically induced (dextran sulfate sodium) colitis (Park 2017).

For more on the dendritic-cell — T-cell interaction, see the Vitamin A immune function page, where dendritic-cell biology is covered in more depth (Vitamin A controls the gut-homing imprinting of T cells by mucosal CD103+ DCs).

Back to Table of Contents

Th1 / Th2 Balance and Cytokine Shifting

The Th1/Th2 paradigm divides effector CD4+ T helper cells into two principal phenotypes: Th1 cells produce IFN-γ and IL-2 and orchestrate cellular immunity (killing intracellular bacteria, viruses, and tumor cells), while Th2 cells produce IL-4, IL-5, and IL-13 and orchestrate humoral immunity (B-cell antibody production, eosinophil-mediated parasite defense, allergic responses). Chronic Th2 dominance is associated with allergic disease, atopy, eczema, asthma, and food sensitivities. Chronic Th1 dominance is associated with several autoimmune conditions (multiple sclerosis, Hashimoto's thyroiditis, type 1 diabetes).

Practitioners describe Pau d'Arco as shifting the Th1/Th2 balance toward Th1. The studies found point in different directions depending on what was tested: the whole water extract of the inner bark, given to mice, raised Th2 and regulatory T cells and sharply lowered Th1 and Th17 cells (Park 2017), while isolated beta-lapachone in mouse spleen cells raised the Th1 cytokine IL-2 and lowered the Th2 cytokines IL-4, IL-5, IL-6 and IL-10 (Choi 2012). The practitioners' reasoning runs in two directions:

This caveat is shared with several other immune-stimulating herbs (echinacea, astragalus, andrographis) and is one of the reasons practitioners give for matching "general immune support" herbs to a patient's actual immune phenotype.

Back to Table of Contents

Kallawaya and Guaraní Indigenous Use — Fevers, Wound Healing, Chronic Infection

The Kallawaya healers of the Bolivian Andes are among the few continuously transmitted traditional medical lineages from pre-Columbian South America. UNESCO recognized the Kallawaya cosmovision and herbal medicine system as a Masterpiece of the Oral and Intangible Heritage of Humanity in 2003. Their materia medica includes hundreds of plant species collected from the Amazon basin to the high Andes, with Pau d'Arco occupying a senior position among the "strong" antifungal-antimicrobial-depurative agents.

Documented Kallawaya indications for Pau d'Arco include:

The Guaraní of the southern Brazilian and Paraguayan rainforests used Pau d'Arco (tajy) for similar indications: fevers, infected wounds, parasites, malaria, and general convalescent recovery. The Guaraní name tajy meaning "to have strength/vigor" reflects the herb's reputation as a tonic that restores vitality after debilitating illness — a profile consistent with the modern understanding of its immune-modulating and anti-inflammatory activity.

Back to Table of Contents

Adult Applications — Recurrent Infection, Chronic Sinusitis, Post-Viral Recovery

For adults in the developed world, integrative practitioners describe the immune-modulating uses of Pau d'Arco in a few clinical contexts that draw on the traditional indications; no clinical trial of any of these uses was found:

For people with frank primary or secondary immunodeficiency (human immunodeficiency virus (HIV), post-transplant immunosuppression, primary antibody deficiency), no study of Pau d'Arco was found, and nothing here supports using it in place of medical treatment of these conditions.

Back to Table of Contents

Combining With Other Immune Herbs — Echinacea, Astragalus, Reishi, Cat's Claw

Pau d'Arco is rarely used as a solo immune intervention — experienced integrative practitioners typically combine it with one or more other immune-supporting herbs that work through complementary mechanisms:

A typical "chronic recurrent infection" protocol might combine Pau d'Arco (steady tonic dose, weeks to months) + Astragalus (steady tonic dose, weeks to months) + Reishi (steady tonic dose), with Echinacea or Andrographis added acutely at first sign of new infection. The herbs are usually rotated on 8-12 week cycles to prevent tachyphylaxis.

Back to Table of Contents

Cautions Specific to Immune-Modulating Use

The general cautions covered on the Cautions & Cancer Research page apply equally to immune-modulating use. A few use-specific points worth emphasizing:

Back to Table of Contents

Key Research Papers

  1. de Lima OG, d'Albuquerque IL, Maciel GM, Maciel MC (1962). Antimicrobial substances of higher plants. Anais (Brazilian early lapachol characterization work). — PubMed
  2. Liu SH, Tzeng HP, Kuo ML, Lin-Shiau SY (1999). Inhibition of inducible nitric oxide synthase by beta-lapachone in rat alveolar macrophages and aorta. British Journal of Pharmacology. 126(3):746-750. — PubMed PMID: 10188987
  3. Tzeng HP, Ho FM, Chao KF, Kuo ML, Lin-Shiau SY, Liu SH (2003). beta-Lapachone reduces endotoxin-induced macrophage activation and lung edema and mortality. American Journal of Respiratory and Critical Care Medicine. 168(1):85-91. — PubMed PMID: 12724123
  4. Byeon SE, Chung JY, Lee YG, Kim BH, Kim KH, Cho JY (2008). In vitro and in vivo anti-inflammatory effects of taheebo, a water extract from the inner bark of Tabebuia avellanedae. Journal of Ethnopharmacology. 119(1):145-152. — PubMed PMID: 18634864
  5. Park HJ, Lee SW, Kwon DJ, Heo SI, Park SH, Kim SY, Hong S (2017). Oral administration of taheebo (Tabebuia avellanedae Lorentz ex Griseb.) water extract prevents DSS-induced colitis in mice by up-regulating type II T helper immune responses. BMC Complementary and Alternative Medicine. 17(1):448. — PubMed PMID: 28877696
  6. Choi M, Park I, Ju J, Park KY, Kim KH (2012). Effects of β-lapachone on the production of Th1 and Th2 cytokines in C57BL/6 mice. Journal of Environmental Pathology, Toxicology and Oncology. 31(2):87-94. — PubMed PMID: 23216634
  7. Maeda M, Murakami M, Takegami T, Ota T (2008). Promotion or suppression of experimental metastasis of B16 melanoma cells after oral administration of lapachol. Toxicology and Applied Pharmacology. 229(2):232-238. — PubMed PMID: 18294668
  8. de Almeida ER, Lucena FR, Silva CV, da Silva Costa-Junior W, Cavalcanti JB, Couto GB, da Silva LL, da Mota DL, da Silveira AB, de Sousa Filho SD, da Silva AC (2009). Toxicological assessment of beta-lapachone on organs from pregnant and non-pregnant rats. Phytotherapy Research. 23(9):1276-1280. — PubMed PMID: 19197915
  9. Giacomelli I, Scartoni D, Fiammetta M, Baki M, Zei G, Muntoni C, Cappelli S, Greto D, Scoccianti S, Livi L (2015). Oral lapacho-based medication: an easy, safe, and feasible support to prevent and/or reduce oral mucositis during radiotherapy for head and neck cancer. Nutrition and Cancer. 67(8):1247-1253. — PubMed PMID: 26451712
  10. Awale S, Kawakami T, Tezuka Y, Ueda JY, Tanaka K, Kadota S (2005). Nitric oxide (NO) production inhibitory constituents of Tabebuia avellanedae from Brazil. Chemical and Pharmaceutical Bulletin. 53(6):710-713. — PubMed PMID: 15930790
  11. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A (2002). Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends in Immunology. 23(11):549-555. (Background on M1/M2 macrophage polarization.) — PubMed PMID: 12401408
  12. Calabrese EJ (2008). Hormesis and medicine. British Journal of Clinical Pharmacology. 66(5):594-617. — PubMed PMID: 18662293
  13. Bastos GN, Santos AR, Ferreira VM, Costa AM, Bispo CI, Silveira AJ, Do Nascimento JL (2006). Antinociceptive effect of the aqueous extract obtained from roots of Physalis angulata L. on mice. Journal of Ethnopharmacology. 103(2):241-245. (A pain study of a different Brazilian plant; it contains no Pau d'Arco or immune data.) — PubMed PMID: 16169699

PubMed Topic Searches

  1. PubMed: Tabebuia immune modulation NK / macrophage
  2. PubMed: Beta-lapachone macrophage TNF / NO
  3. PubMed: Naphthoquinone Th1/Th2 balance
  4. PubMed: Kallawaya Andean depurative herbs
  5. PubMed: Pau d'Arco chronic fatigue / post-viral

Back to Table of Contents

Connections

Back to Table of Contents